Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study
Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed the superiority of its secukinumab (AIN457) in clearing skin compared to Enbrel (etanercept), which is made by US biotech leader Amgen’s (Nasdaq: AMGN) and earned sales of $1.3 billion last year.
The FIXTURE trial was a randomized, double-blind, double-dummy, placebo-controlled, multi-center global study of subcutaneous secukinumab in moderate-to-severe plaque psoriasis, involving 1,307 patients.
The study showed that all primary and secondary endpoints were met. Established treatment measures were used to assess the efficacy of secukinumab including PASI 75 (Psoriasis Area and Severity Index 75) and the Investigator's Global Assessment (IGA mod 2011), a standard tool to assess the clearing of skin after treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze